Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Plavix | Stroke | Thrombosis